Sponsors (7)
The bill invests federal resources to create regional, open‑access bioindustrial scale‑up facilities that can accelerate commercialization, workforce growth, and domestic supply‑chain resilience, at the cost of modest federal spending and potential risks to private investment incentives, biosecurity oversight, and implementation effectiveness.
Researchers, startups, and small biotech companies gain access to at least two pre‑commercial bioindustrial facilities for pilot, demonstration, and scale‑up work, lowering technical risk and making commercialization more feasible.
Regional communities and workers (including students and rural areas) gain new workforce training opportunities and jobs through geographically distributed facilities coordinated with local workforce programs.
The program builds domestic biomanufacturing capacity and a coordinated network of facilities that can strengthen supply‑chain resilience for chemicals and materials important to industry and state economies.
The open‑access and public‑domain IP requirements could discourage private partners or reduce incentives for private investment that depends on exclusive licensing or proprietary advantages.
Broad open‑access and data‑sharing priorities, if not tightly governed, could increase biosecurity and sensitive data‑sharing risks for the public and research community.
Taxpayers would ultimately bear up to $225.5 million in authorized federal spending for facility construction and operations over FY2026–2030.
Based on analysis of 3 sections of legislative text.
Adds biomanufacturing definitions and requires DOE to establish at least two open‑access bioindustrial technology maturation user facilities by Sept 30, 2030.
Official title: To amend the Energy Policy Act of 2005 to support the development, demonstration, and commercial application of biotechnology products to increase energy resiliency, and for other purposes.
Introduced March 16, 2026 by James Baird · Last progress March 16, 2026
Creates new definitions for biomanufacturing and related terms in the Department of Energy’s bioenergy statute and requires the Department to establish at least two open‑access bioindustrial technology maturation facilities by September 30, 2030. These user facilities will be precommercial centers that provide infrastructure, R&D, demonstration, and de‑risking activities to help scale biotechnology products and processes and to make specialized biomanufacturing capabilities broadly available to public and private users.